Deferasirox (BioDeep_00000397791)
natural product
代谢物信息卡片
4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
化学式: C21H15N3O4 (373.10625100000004)
中文名称: 地拉罗司
谱图信息:
最多检出来源 Homo sapiens(natural_products) 50%
分子结构信息
SMILES: C1=CC(=CC=C1C(O)=O)N2C(=NC(=N2)C3=CC=CC=C3O)C4=CC=CC=C4O
InChI: InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
描述信息
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AC - Iron chelating agents
D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents
CONFIDENCE standard compound; EAWAG_UCHEM_ID 2842
EAWAG_UCHEM_ID 2842; CONFIDENCE standard compound
同义名列表
数据库引用编号
22 个数据库交叉引用编号
- ChEBI: CHEBI:49005
- KEGGdrug: D03669
- PubChem: 214348
- PubChem: 5493381
- Metlin: METLIN85530
- DrugBank: DB01609
- ChEMBL: CHEMBL550348
- MeSH: Deferasirox
- CAS: 1044764-54-6
- CAS: 201530-41-8
- MoNA: CCMSLIB00000078246
- MoNA: EQ284256
- MoNA: EQ284255
- MoNA: EQ284254
- MoNA: EQ284253
- MoNA: EQ284252
- MoNA: EQ284251
- MoNA: EQ284206
- MoNA: EQ284205
- MoNA: EQ284203
- MoNA: EQ284202
- MoNA: EQ284201
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Nadeen Diaa Abdel-Wahab, Mohamed Fawzi Kabil, Ibrahim M El-Sherbiny, Mohamed F Salama, Gehad El-Sayed, El-Said El-Sherbini. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment: in-vitro and in-vivo evaluation.
Drug development and industrial pharmacy.
2024 Mar; 50(3):223-235. doi:
10.1080/03639045.2024.2314189. [PMID: 38305197] - Tingjunhong Ni, Xiaochen Chi, Hao Wu, Fei Xie, Junhe Bao, Jiayin Wang, Zhe Ji, Liping Li, Xiaobo Wang, Lan Yan, Yumeng Hao, Dazhi Zhang, Yuanying Jiang. Design, synthesis and evaluation of novel deferasirox derivatives with high antifungal potency in vitro and in vivo.
European journal of medicinal chemistry.
2024 Jan; 264(?):116026. doi:
10.1016/j.ejmech.2023.116026. [PMID: 38070429] - Kosei Ishimaru, Masataka Ikeda, Hiroko Deguchi Miyamoto, Shun Furusawa, Ko Abe, Masatsugu Watanabe, Takuya Kanamura, Satoshi Fujita, Ryohei Nishimura, Takayuki Toyohara, Shouji Matsushima, Tomoko Koumura, Ken-Ichi Yamada, Hirotaka Imai, Hiroyuki Tsutsui, Tomomi Ide. Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A.
Journal of the American Heart Association.
2024 Jan; 13(1):e031219. doi:
10.1161/jaha.123.031219. [PMID: 38158218] - Komal Thapa, Thakur Gurjeet Singh, Amarjot Kaur. Targeting ferroptosis in ischemia/reperfusion renal injury.
Naunyn-Schmiedeberg's archives of pharmacology.
2022 11; 395(11):1331-1341. doi:
10.1007/s00210-022-02277-5. [PMID: 35920897] - Mohamed Fawzi Kabil, Mohamed Y Mahmoud, Alaa F Bakr, Dalia Zaafar, Ibrahim M El-Sherbiny. Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity.
Life sciences.
2022 Sep; 305(?):120731. doi:
10.1016/j.lfs.2022.120731. [PMID: 35753435] - Wataru Jomen, Takaaki Ohtake, Takayuki Akita, Daisuke Suto, Hideki Yagi, Yosuke Osawa, Yutaka Kohgo. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Sep; 153(?):113363. doi:
10.1016/j.biopha.2022.113363. [PMID: 35834989] - Elisa Borella, Sean Oosterholt, Paolo Magni, Oscar Della Pasqua. Characterisation of individual ferritin response in patients receiving chelation therapy.
British journal of clinical pharmacology.
2022 Aug; 88(8):3683-3694. doi:
10.1111/bcp.15290. [PMID: 35199367] - Nan Zhou, Yan Cui, Rui Zhu, Yuhuan Kuang, Wenhui Ma, Jianyuan Hou, Yumeng Zhu, Shubo Chen, Xin Xu, Ke Tan, Pengxiu Cao, Xianglin Duan, Yumei Fan. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Gynecologic oncology.
2022 Jul; 166(1):126-137. doi:
10.1016/j.ygyno.2022.05.006. [PMID: 35688655] - Pavlína Hašková, Lenka Applová, Hana Jansová, Pavel Homola, Katherine J Franz, Kateřina Vávrová, Jaroslav Roh, Tomáš Šimůnek. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Scientific reports.
2022 06; 12(1):9765. doi:
10.1038/s41598-022-13554-x. [PMID: 35697900] - Ahmad Zargari, Simon Wu, Anthea Greenway, Ken Cheng, Zane Kaplan. Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major.
Vox sanguinis.
2022 May; 117(5):733-737. doi:
10.1111/vox.13248. [PMID: 35014065] - Maddalena Casale, Gian Luca Forni, Elena Cassinerio, Daniela Pasquali, Raffaella Origa, Marilena Serra, Saveria Campisi, Angelo Peluso, Roberta Renni, Alessandro Cattoni, Elisa De Michele, Massimo Allò, Maurizio Poggi, Francesca Ferrara, Rosanna Di Concilio, Filomena Sportelli, Antonella Quarta, Maria Caterina Putti, Lucia Dora Notarangelo, Antonella Sau, Saverio Ladogana, Immacolata Tartaglione, Stefania Picariello, Alessia Marcon, Patrizia Sturiale, Domenico Roberti, Antonio Ivan Lazzarino, Silverio Perrotta. Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort.
Haematologica.
2022 02; 107(2):467-477. doi:
10.3324/haematol.2020.272419. [PMID: 33406815] - Mojgan Nazari, Kenneth W Ho, Natasha Langley, Kuan M Cha, Raymond Kodsi, Mawson Wang, D Ross Laybutt, Kim Cheng, Rebecca A Stokes, Michael M Swarbrick, Jenny E Gunton. Iron chelation increases beige fat differentiation and metabolic activity, preventing and treating obesity.
Scientific reports.
2022 01; 12(1):776. doi:
10.1038/s41598-022-04809-8. [PMID: 35031684] - Ola E Nafea, Marwa Zakaria, Tamer Hassan, Sherif M El Gebaly, Hosam E Salah. Subclinical nephrotoxicity in patients with beta-thalassemia: role of urinary kidney injury molecule.
Drug and chemical toxicology.
2022 Jan; 45(1):93-102. doi:
10.1080/01480545.2019.1660362. [PMID: 31905029] - Funda T Kupesiz, Cigdem Sivrice, Aysenur Akinel, Gulen T Kintrup, Elif Guler, Alphan Kupesiz. Efficacy and Safety of Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Thalassemia Patients: A Retrospective Observational Study.
Journal of pediatric hematology/oncology.
2022 01; 44(1):e26-e34. doi:
10.1097/mph.0000000000002328. [PMID: 34986131] - Osama Tanous, Yossi Azulay, Raphael Halevy, Tal Dujovny, Neta Swartz, Raul Colodner, Ariel Koren, Carina Levin. Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.
BMC nephrology.
2021 12; 22(1):418. doi:
10.1186/s12882-021-02630-5. [PMID: 34930156] - Wendi Han, Chenfang Miao, Xintian Zhang, Yinning Lin, Xiaoli Hao, Zhengjun Huang, Shaohuang Weng, Xinhua Lin, Xianzhong Guo, Jianyong Huang. A signal-off fluorescent strategy for deferasirox effective detection using carbon dots as probe and Cu2+ as medium.
Analytica chimica acta.
2021 Sep; 1179(?):338853. doi:
10.1016/j.aca.2021.338853. [PMID: 34535261] - Lorenzo Palagi, Enza Di Gregorio, Diana Costanzo, Rachele Stefania, Camilla Cavallotti, Martina Capozza, Silvio Aime, Eliana Gianolio. Fe(deferasirox)2: An Iron(III)-Based Magnetic Resonance Imaging T1 Contrast Agent Endowed with Remarkable Molecular and Functional Characteristics.
Journal of the American Chemical Society.
2021 09; 143(35):14178-14188. doi:
10.1021/jacs.1c04963. [PMID: 34432442] - Rana M Adel, Rania A Lotfy, Atef S Darwish, Amany S Amer. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox.
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS).
2021 Sep; 67(?):126794. doi:
10.1016/j.jtemb.2021.126794. [PMID: 34052583] - Isita Tripathy, Amrita Panja, Tuphan Kanti Dolai, Asim Kumar Mallick. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
Hemoglobin.
2021 Sep; 45(5):296-302. doi:
10.1080/03630269.2021.1999258. [PMID: 34758688] - Carmen Niño Taravilla, Áurea Cervera Bravo, Hugo Otaola Arca, Julián Sevilla, Cristina Aparicio López. [Deferasirox and Complex Proximal Tubulopathy. Presentation of two clinical cases].
Andes pediatrica : revista Chilena de pediatria.
2021 Aug; 92(4):584-589. doi:
10.32641/andespediatr.v92i4.3154. [PMID: 34652377] - Hasna Qatrunnada, Suharjono, Siprianus Ugroseno Yudho Bintoro, Siti Wahyuni. Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya.
Journal of basic and clinical physiology and pharmacology.
2021 Jun; 32(4):611-616. doi:
10.1515/jbcpp-2020-0429. [PMID: 34214358] - Andrea Piolatto, Paola Berchialla, Sarah Allegra, Silvia De Francia, Giovanni Battista Ferrero, Antonio Piga, Filomena Longo. Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.
Scientific reports.
2021 06; 11(1):12581. doi:
10.1038/s41598-021-91983-w. [PMID: 34131221] - Victoria Birlutiu, Rares Mircea Birlutiu, Liana Chicea. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Medicine.
2021 May; 100(18):e25832. doi:
10.1097/md.0000000000025832. [PMID: 33950993] - Krisada Theppornpitak, Bussaba Trakarnsanga, Supanun Lauhasurayotin, Hansamon Poparn, Kanhatai Chiengthong, Darintr Sosothikul, Piti Techavichit. A Study to Assess and Improve Adherence to Iron Chelation Therapy in Transfusion-Dependent Thalassemia Patients.
Hemoglobin.
2021 May; 45(3):171-174. doi:
10.1080/03630269.2021.1934010. [PMID: 34102943] - Awais Tahir, Syed Ibrar Hussain, Huma Saleem Khan, Sumaira Khalil, Syed Zulfiqar Haider, Munir Akmal Lodhi. Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.
Journal of Ayub Medical College, Abbottabad : JAMC.
2021 Apr; 33(2):207-212. doi:
. [PMID: 34137530] - Abbas Rahdar, Mohammad Reza Hajinezhad, Saman Sargazi, Muhammad Bilal, Mahmood Barani, Pouya Karimi, George Z Kyzas. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
Life sciences.
2021 Apr; 270(?):119146. doi:
10.1016/j.lfs.2021.119146. [PMID: 33545199] - Rajeswari Rethinaswamy DivakarJose, C G Delhikumar, G Ram Kumar. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
Indian journal of pediatrics.
2021 04; 88(4):330-335. doi:
10.1007/s12098-020-03442-5. [PMID: 32661609] - Naja Nyffenegger, Anna Flace, Cédric Doucerain, Franz Dürrenberger, Vania Manolova. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
International journal of molecular sciences.
2021 Jan; 22(2):. doi:
10.3390/ijms22020873. [PMID: 33467196] - Takahiko Imai, Shohei Tsuji, Hirohumi Matsubara, Takuya Ohba, Tomoki Sugiyama, Shinsuke Nakamura, Hideaki Hara, Masamitsu Shimazawa. Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models.
Naunyn-Schmiedeberg's archives of pharmacology.
2021 01; 394(1):73-84. doi:
10.1007/s00210-020-01963-6. [PMID: 32808069] - M Rahmani, M Tavalaee, M Hosseini, A Eskandari, E Shaygannia, N Sadeghi, M N Nazem, P Gharagozloo, J R Drevet, M H Nasr-Esfahani. Deferasirox, an Iron-Chelating Agent, Improves Testicular Morphometric and Sperm Functional Parameters in a Rat Model of Varicocele.
Oxidative medicine and cellular longevity.
2021; 2021(?):6698482. doi:
10.1155/2021/6698482. [PMID: 33897943] - Fouzia N Aboobacker, Gaurav Dixit, Kavitha M Lakshmi, Anu Korula, Aby Abraham, Biju George, Vikram Mathews, Alok Srivastava. Outcome of iron reduction therapy in ex-thalassemics.
PloS one.
2021; 16(1):e0238793. doi:
10.1371/journal.pone.0238793. [PMID: 33481797] - Jinliang Chen, Yichao Xu, Honggang Lou, Bo Jiang, Rong Shao, Dandan Yang, Yin Hu, Zourong Ruan. Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction.
European journal of drug metabolism and pharmacokinetics.
2020 Dec; 45(6):761-770. doi:
10.1007/s13318-020-00647-z. [PMID: 32930952] - Natalia Scaramellini, Dario Consonni, Elena Cassinerio, Carola Arighi, Alessia Marcon, Giovanna Graziadei, Maria Domenica Cappellini, Irene Motta. A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 μg/L.
American journal of hematology.
2020 09; 95(9):E230-E232. doi:
10.1002/ajh.25860. [PMID: 32390147] - Zenshi Miyake, Kiyotaka Nakamagoe, Kunihiro Yoshida, Tadashi Kondo, Akira Tamaoka. Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature.
Internal medicine (Tokyo, Japan).
2020 Jul; 59(14):1755-1761. doi:
10.2169/internalmedicine.4178-19. [PMID: 32238721] - Mousumee Panigrahi, Trupti Rekha Swain, Rabindra Kumar Jena, Ashutosh Panigrahi, Nishant Debta. Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha.
Indian journal of pharmacology.
2020 May; 52(3):172-178. doi:
10.4103/ijp.ijp_68_18. [PMID: 32873999] - Emanuele Angelucci, Junmin Li, Peter Greenberg, Depei Wu, Ming Hou, Efreen Horacio Montano Figueroa, Maria Guadalupe Rodriguez, Xunwei Dong, Jagannath Ghosh, Miguel Izquierdo, Guillermo Garcia-Manero. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Annals of internal medicine.
2020 04; 172(8):513-522. doi:
10.7326/m19-0916. [PMID: 32203980] - Eman Mostafa Hamed, Mohamed Hussein Meabed, Raghda R S Hussein, Usama Farghaly Aly. Recent insight on improving the iron chelation efficacy of deferasirox by adjuvant therapy in transfusion dependent beta thalassemia children with sluggish response.
Expert opinion on drug metabolism & toxicology.
2020 Mar; 16(3):179-193. doi:
10.1080/17425255.2020.1729353. [PMID: 32067512] - Esther M Gottwald, Claus D Schuh, Patrick Drücker, Dominik Haenni, Adam Pearson, Susan Ghazi, Milica Bugarski, Marcello Polesel, Michael Duss, Ehud M Landau, Andres Kaech, Urs Ziegler, Anne K M Lundby, Carsten Lundby, Petra S Dittrich, Andrew M Hall. The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability.
Scientific reports.
2020 01; 10(1):1577. doi:
10.1038/s41598-020-58386-9. [PMID: 32005861] - Kangna Cao, Guanghui Ren, Chengcan Lu, Yao Wang, Yanan Tan, Jing Zhou, Yongjie Zhang, Yang Lu, Ning Li, Xijing Chen, Di Zhao. ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects.
European journal of clinical pharmacology.
2020 Jan; 76(1):51-59. doi:
10.1007/s00228-019-02775-1. [PMID: 31677118] - Giovanna Capolongo, Miriam Zacchia, Amerigo Beneduci, Silvia Costantini, Patrizia Cinque, Anna Spasiano, Giuseppina De Luca, Maria Enrica Di Pietro, Paolo Ricchi, Francesco Trepiccione, Giovambattista Capasso, Aldo Filosa. Urinary Metabolic Profile of Patients with Transfusion-Dependent β-Thalassemia Major Undergoing Deferasirox Therapy.
Kidney & blood pressure research.
2020; 45(3):455-466. doi:
10.1159/000507369. [PMID: 32434200] - Hayder Al-Momen, Hussein Khudhair Hussein, Zaid Al-Attar, Mohammed Jalal Hussein. Green tea influence on iron overload in thalassemia intermedia patients: a randomized controlled trial.
F1000Research.
2020; 9(?):1136. doi:
10.12688/f1000research.25553.1. [PMID: 33024552] - Mehran Karimi, Sezaneh Haghpanah, Gholamreza Bahoush, Shahla Ansari, Azita Azarkeivan, Amin Shahsavani, Asghar Bazrafshan, Ali Jangjou. Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia.
Journal of pediatric hematology/oncology.
2020 01; 42(1):23-26. doi:
10.1097/mph.0000000000001596. [PMID: 31568183] - Amal El-Beshlawy, Baba Inusa, David Beneitez Pastor, Blanca Xicoy, Maria Soledada Duran Nieto, Andreas Bruederle, Amin Azmon, Geralyn Gilotti, Mohsen Elalfy. International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
Hematology (Amsterdam, Netherlands).
2019 Dec; 24(1):238-246. doi:
10.1080/16078454.2018.1558758. [PMID: 30558524] - Aziz Eghbali, Atefeh Khalilpour, Hassan Taherahmadi, Bahador Bagheri. Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study.
Therapie.
2019 Oct; 74(5):507-512. doi:
10.1016/j.therap.2018.11.013. [PMID: 30704764] - Sarah Allegra, Jessica Cusato, Silvia De Francia, Filomena Longo, Elisa Pirro, Davide Massano, Valeria Avataneo, Amedeo De Nicolò, Antonio Piga, Antonio D'Avolio. The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients.
The pharmacogenomics journal.
2019 10; 19(5):417-427. doi:
10.1038/s41397-019-0071-7. [PMID: 30651574] - Nashwan M Al Hafidh. Efficacy Of Interrupted And Modified Deferasirox Dose Among Paediatric Patients With Β- Thalassemia Major And High Alanine Aminotransferase Level.
Journal of Ayub Medical College, Abbottabad : JAMC.
2019 Apr; 31(2):182-184. doi:
NULL. [PMID: 31094112] - Chien-Heng Lin, Xianxiu Chen, Chin-Ching Wu, Kang-Hsi Wu, Ta-Shu Song, Te-Fu Weng, Yow-Wen Hsieh, Ching-Tien Peng. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Expert review of hematology.
2019 04; 12(4):265-272. doi:
10.1080/17474086.2019.1593823. [PMID: 30920854] - Bulent Antmen, Zeynep Karakaş, Mehmet Akif Yeşilipek, Osman Alphan Küpesiz, İlgen Şaşmaz, Vedat Uygun, Erdal Kurtoğlu, Gonul Oktay, Gonul Aydogan, Mehmet Akın, Zafer Salcioglu, Canan Vergin, Elif Güler Kazancı, Selma Ünal, Ümran Çalışkan, Yusuf Ziya Aral, Emine Türkkan, Adalet Meral Güneş, Bahattin Tunç, Fatma Gümrük, Aylin Canbolat Ayhan, Murat Söker, Ahmet Koç, Yeşim Oymak, Mehmet Ertem, Çetin Timur, Yıldız Yıldırmak, Gülersu İrken, Hilmi Apak, Betül Biner, Tuğba Gürleyen Eren, Yasemin Işık Balcı, Ülker Koçak, Gülsün Karasu, Diyar Akkaynak, Türkan Patıroğlu. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
European journal of haematology.
2019 Feb; 102(2):123-130. doi:
10.1111/ejh.13180. [PMID: 30300449] - Byung-Sik Cho, Young-Woo Jeon, A-Reum Hahn, Tai-Hyang Lee, Sung-Soo Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong-Wook Lee, Woo-Sung Min, Hee-Je Kim. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia.
Cancer medicine.
2019 02; 8(2):501-514. doi:
10.1002/cam4.1928. [PMID: 30677244] - Steven T Bird, Richard S Swain, Fang Tian, Olanrewaju O Okusanya, Peter Waldron, Mona Khurana, Elizabeth L Durmowicz, Yong Ma, Jacqueline M Major, Kate Gelperin. Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies.
The Lancet. Child & adolescent health.
2019 01; 3(1):15-22. doi:
10.1016/s2352-4642(18)30335-3. [PMID: 30455109] - Hamidreza Badeli, Adel Baghersalimi, Sajjad Eslami, Farshid Saadat, Afagh Hassanzadeh Rad, Rokhsar Basavand, Soghra Rafiei Papkiadeh, Bahram Darbandi, Wesam Kooti, Ilaria Peluso. Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study.
Oxidative medicine and cellular longevity.
2019; 2019(?):5461617. doi:
10.1155/2019/5461617. [PMID: 31178966] - Nancy F Olivieri, Amir Sabouhanian, Brenda L Gallie. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
PloS one.
2019; 14(2):e0211942. doi:
10.1371/journal.pone.0211942. [PMID: 30811439] - Keiko Oda, Kan Katayama, Akiko Tanoue, Tomohiro Murata, Yumi Hirota, Shoko Mizoguchi, Yosuke Hirabayashi, Takayasu Ito, Eiji Ishikawa, Kaoru Dohi, Masaaki Ito. Acute kidney injury due to thin basement membrane disease mimicking Deferasirox nephrotoxicity: a case report.
BMC nephrology.
2018 12; 19(1):363. doi:
10.1186/s12882-018-1180-2. [PMID: 30558557] - Sarah Allegra, Jessica Cusato, Silvia De Francia, Filomena Longo, Elisa Pirro, Davide Massano, Valeria Avataneo, Amedeo De Nicolò, Antonio Piga, Antonio D'Avolio. Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients.
Pharmacogenetics and genomics.
2018 09; 28(9):199-206. doi:
10.1097/fpc.0000000000000348. [PMID: 30179981] - Erwin Yii, James Cg Doery, Zane Kaplan, Peter G Kerr. Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients.
Nephrology (Carlton, Vic.).
2018 Sep; 23(9):887-889. doi:
10.1111/nep.13389. [PMID: 29663590] - Florian Nolte, Holger Nückel, Burkhard Schmidt, Thomas Geer, Oleg Rubanov, Holger Hebart, Andrea Jarisch, Stefan Albrecht, Christiane Johr, Christiane Schumann, Wolf-Karsten Hofmann. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Journal of cancer research and clinical oncology.
2018 Aug; 144(8):1531-1538. doi:
10.1007/s00432-018-2665-x. [PMID: 29761371] - Zeynep Karakas, Yasin Yilmaz, Zuhal Bayramoglu, Serap Karaman, Selime Aydogdu, Ayse Ozkan Karagenc, Deniz Tugcu, Memduh Dursun. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
La Radiologia medica.
2018 Aug; 123(8):572-576. doi:
10.1007/s11547-018-0889-0. [PMID: 29663188] - Raffaella Origa, Antonio Piga, Immacolata Tartaglione, Giuseppina Della Corte, Gian Luca Forni, Andreas Bruederle, Chiara Castiglioni, Jackie Han. Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias.
American journal of hematology.
2018 07; 93(7):E172-E175. doi:
10.1002/ajh.25122. [PMID: 29675847] - A M Mohsin, M K Hassan. A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, Southern Iraq.
Nigerian journal of clinical practice.
2018 Jun; 21(6):735-742. doi:
10.4103/njcp.njcp_162_17. [PMID: 29888721] - Kannan Sridharan, Gowri Sivaramakrishnan. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Expert review of clinical pharmacology.
2018 Jun; 11(6):641-650. doi:
10.1080/17512433.2018.1473760. [PMID: 29727586] - S Allegra, J Cusato, S De Francia, A Arduino, F Longo, E Pirro, D Massano, A De Nicolò, A Piga, A D'Avolio. Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.
The pharmacogenomics journal.
2018 05; 18(3):506-515. doi:
10.1038/tpj.2017.43. [PMID: 29160302] - Tengfei Li, Zhimin Cui, Yan Wang, Wen Yang, Duo Li, QinXin Song, Luning Sun, Li Ding. A simple LC-MS/MS method for determination of deferasirox in human plasma: Troubleshooting of interference from ferric ion in method development and its application.
Journal of pharmaceutical and biomedical analysis.
2018 Mar; 151(?):145-150. doi:
10.1016/j.jpba.2017.12.052. [PMID: 29328981] - Vicki Osborne, Miranda Davies, Deborah Layton, Saad A W Shakir. Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England.
Drug safety.
2018 03; 41(3):267-275. doi:
10.1007/s40264-017-0606-2. [PMID: 29019038] - Mehmet Akif Yesilipek, Gulsun Karasu, Zuhre Kaya, Baris B Kuskonmaz, Vedat Uygun, Ilkiz Dag, Onur Ozudogru, Mehmet Ertem. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2018 03; 24(3):613-618. doi:
10.1016/j.bbmt.2017.11.006. [PMID: 29155313] - Sarah Allegra, Davide Massano, Silvia De Francia, Filomena Longo, Francesca Piccione, Elisa Pirro, Jessica Cusato, Antonio D'Avolio, Antonio Piga. Clinical relevance of deferasirox trough levels in β-thalassemia patients.
Clinical and experimental pharmacology & physiology.
2018 02; 45(2):213-216. doi:
10.1111/1440-1681.12879. [PMID: 29205450] - Sarah Allegra, Jessica Cusato, Silvia De Francia, Filomena Longo, Elisa Pirro, Davide Massano, Antonio Piga, Antonio D'Avolio. Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children.
Pharmacogenetics and genomics.
2018 Jan; 28(1):17-22. doi:
10.1097/fpc.0000000000000315. [PMID: 29099735] - Elliott Vichinsky, Amal El-Beshlawy, Azzam Al Zoebie, Annie Kamdem, Suzanne Koussa, Thirachit Chotsampancharoen, Andreas Bruederle, Geralyn Gilotti, Jackie Han, Mohsen Elalfy. Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
Pediatric blood & cancer.
2017 Sep; 64(9):. doi:
10.1002/pbc.26507. [PMID: 28296163] - Claudia Bollig, Lisa K Schell, Gerta Rücker, Roman Allert, Edith Motschall, Charlotte M Niemeyer, Dirk Bassler, Joerg J Meerpohl. Deferasirox for managing iron overload in people with thalassaemia.
The Cochrane database of systematic reviews.
2017 08; 8(?):CD007476. doi:
10.1002/14651858.cd007476.pub3. [PMID: 28809446] - Turan Bayhan, Şule Ünal, Eyüp Çırak, Onur Erdem, Cemal Akay, Orhan Gürsel, İbrahim Eker, Erdem Karabulut, Fatma Gümrük. Heavy metal levels in patients with ineffective erythropoiesis.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
2017 Aug; 56(4):539-543. doi:
10.1016/j.transci.2017.07.021. [PMID: 28818403] - Sergio A Loza-Rosas, Alexandra M Vázquez-Salgado, Kennett I Rivero, Lenny J Negrón, Yamixa Delgado, Josué A Benjamín-Rivera, Angel L Vázquez-Maldonado, Timothy B Parks, Charlene Munet-Colón, Arthur D Tinoco. Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
Inorganic chemistry.
2017 Jul; 56(14):7788-7802. doi:
10.1021/acs.inorgchem.7b00542. [PMID: 28644630] - Sarah Allegra, Jessica Cusato, Silvia De Francia, Elisa Pirro, Davide Massano, Antonio Piga, Antonio D'Avolio. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
The Journal of pharmacy and pharmacology.
2017 May; 69(5):525-528. doi:
10.1111/jphp.12559. [PMID: 27230486] - Turan Bayhan, Şule Ünal, Ozan Ünlü, Hakan Küçüker, Anıl Doğukan Tutal, Erdem Karabulut, Fatma Gümrük. The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation.
Hematology (Amsterdam, Netherlands).
2017 May; 22(4):248-251. doi:
10.1080/10245332.2016.1252004. [PMID: 27809710] - Ali T Taher, Raffaella Origa, Silverio Perrotta, Alexandra Kourakli, Giovan Battista Ruffo, Antonis Kattamis, Ai-Sim Goh, Annelore Cortoos, Vicky Huang, Marine Weill, Raquel Merino Herranz, John B Porter. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
American journal of hematology.
2017 May; 92(5):420-428. doi:
10.1002/ajh.24668. [PMID: 28142202] - Meng-Yao Lu, Ting-Hao Lin, Po-Hung Chiang, Pei-Hsin Kuo, Ning Wang, Wen-Hsin Wu, Kai-Hsin Lin, Tzu-Hua Wu. Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major.
Therapeutic drug monitoring.
2017 04; 39(2):185-191. doi:
10.1097/ftd.0000000000000378. [PMID: 28141745] - Lisette Del Corso, Lucia Biale, Emanuele Luigi Parodi, Rodolfo Russo, Rosa Filiberti, Eleonora Arboscello. Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
International journal of clinical oncology.
2017 Apr; 22(2):380-386. doi:
10.1007/s10147-016-1042-5. [PMID: 27771776] - Nupur Parakh, Jagdish Chandra, Sunita Sharma, Bhavna Dhingra, Rajesh Jain, DeoNath Mahto. Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
Journal of pediatric hematology/oncology.
2017 04; 39(3):209-213. doi:
10.1097/mph.0000000000000780. [PMID: 28221264] - Sarah Allegra, Silvia De Francia, Jessica Cusato, Arianna Arduino, Davide Massano, Filomena Longo, Antonio Piga, Antonio D'Avolio. Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.
Pharmacogenomics.
2017 Apr; 18(6):539-554. doi:
10.2217/pgs-2016-0176. [PMID: 28346059] - John B Porter, Mohsen Elalfy, Ali Taher, Yesim Aydinok, Szu-Hee Lee, Pranee Sutcharitchan, Ali El-Ali, Jackie Han, Amal El-Beshlawy. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
European journal of haematology.
2017 Mar; 98(3):280-288. doi:
10.1111/ejh.12830. [PMID: 27859648] - Diego Martin-Sanchez, Angel Gallegos-Villalobos, Miguel Fontecha-Barriuso, Susana Carrasco, Maria Dolores Sanchez-Niño, Francisco J Lopez-Hernandez, Marta Ruiz-Ortega, Jesus Egido, Alberto Ortiz, Ana Belén Sanz. Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells.
Scientific reports.
2017 01; 7(?):41510. doi:
10.1038/srep41510. [PMID: 28139717] - Mehran Karimi, Abbas Avazpour, Sezaneh Haghpanah, Foroogh Toosi, Arash Badie. Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
Journal of pediatric hematology/oncology.
2017 01; 39(1):e11-e14. doi:
10.1097/mph.0000000000000658. [PMID: 27548339] - Ampaiwan Chuansumrit, Pimprae Pengpis, Pat Mahachoklertwattana, Nongnuch Sirachainan, Preamrudee Poomthavorn, Witaya Sungkarat, Praguywan Kadegasem, Patcharin Khlairit, Pakawan Wongwerawattanakoon. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
Acta haematologica.
2017; 137(1):20-26. doi:
10.1159/000450673. [PMID: 27838686] - Adlette Inati, Mario Kahale, Nada Sbeiti, Maria Domenica Cappellini, Ali T Taher, Suzanne Koussa, Therese A Nasr, Khaled M Musallam, Hussein A Abbas, John B Porter. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Pediatric blood & cancer.
2017 01; 64(1):188-196. doi:
10.1002/pbc.26213. [PMID: 27576370] - Sarah Allegra, Silvia De Francia, Filomena Longo, Davide Massano, Jessica Cusato, Arianna Arduino, Elisa Pirro, Antonio Piga, Antonio D'Avolio. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2016 Dec; 84(?):1510-1512. doi:
10.1016/j.biopha.2016.11.041. [PMID: 27881236] - Hung-Ju Lin, Kun-Pin Hsieh, Shyh-Shin Chiou, Hwang-Shang Kou, Shou-Mei Wu. Determination of deferasirox in human plasma by short-end injection and sweeping with a field-amplified sample stacking and micellar electrokinetic chromatography.
Journal of pharmaceutical and biomedical analysis.
2016 Nov; 131(?):497-502. doi:
10.1016/j.jpba.2016.06.042. [PMID: 27697722] - Sarah Allegra, Silvia De Francia, Jessica Cusato, Elisa Pirro, Davide Massano, Antonio Piga, Antonio D'Avolio. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
The Journal of pharmacy and pharmacology.
2016 Nov; 68(11):1417-1421. doi:
10.1111/jphp.12638. [PMID: 27672004] - Issei Saeki, Naoki Yamamoto, Takahiro Yamasaki, Taro Takami, Masaki Maeda, Koichi Fujisawa, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Koichi Uchida, Kenji Tani, Isao Sakaida. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.
World journal of gastroenterology.
2016 Oct; 22(40):8967-8977. doi:
10.3748/wjg.v22.i40.8967. [PMID: 27833388] - Hassan G Beydoun, Antoine N Saliba, Ali T Taher. Deferasirox in thalassemia patients with end-stage renal disease.
American journal of hematology.
2016 Oct; 91(10):E456-7. doi:
10.1002/ajh.24457. [PMID: 27342388] - Hirofumi Harima, Seiji Kaino, Taro Takami, Shuhei Shinoda, Toshihiko Matsumoto, Koichi Fujisawa, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
BMC cancer.
2016 08; 16(?):702. doi:
10.1186/s12885-016-2744-9. [PMID: 27582255] - Koyelle Papneja, Mihir D Bhatt, Melanie Kirby-Allen, Steven Arora, John T Wiernikowski, Uma H Athale. Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis.
Pediatric blood & cancer.
2016 08; 63(8):1480-3. doi:
10.1002/pbc.25995. [PMID: 27082377] - Jessica Cusato, Sarah Allegra, Silvia De Francia, Davide Massano, Antonio Piga, Antonio D'Avolio. Role of pharmacogenetics on deferasirox AUC and efficacy.
Pharmacogenomics.
2016 04; 17(6):561-72. doi:
10.2217/pgs-2015-0001. [PMID: 27043265] - Sirinart Kumfu, Siriporn C Chattipakorn, Suthat Fucharoen, Nipon Chattipakorn. Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Experimental physiology.
2016 Apr; 101(4):521-39. doi:
10.1113/ep085517. [PMID: 26824522] - Phillip Wong, Kevan Polkinghorne, Peter G Kerr, James C G Doery, Matthew T Gillespie, I Larmour, Peter J Fuller, Donald K Bowden, Frances Milat. Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria.
Bone.
2016 Apr; 85(?):55-8. doi:
10.1016/j.bone.2016.01.011. [PMID: 26802257] - Emanuele Angelucci, Federica Pilo. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.
Annals of the New York Academy of Sciences.
2016 03; 1368(1):115-21. doi:
10.1111/nyas.13027. [PMID: 26999450] - Sunil Gomber, Prachi Jain, Satender Sharma, Manish Narang. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Indian pediatrics.
2016 Mar; 53(3):207-10. doi:
10.1007/s13312-016-0821-4. [PMID: 27029681] - Gizem Esra Genc, Zeynep Ozturk, Saadet Gumuslu, Alphan Kupesiz. Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.
Biological trace element research.
2016 Mar; 170(1):9-16. doi:
10.1007/s12011-015-0441-1. [PMID: 26179086] - Fabio Efficace, Valeria Santini, Giorgio La Nasa, Francesco Cottone, Carlo Finelli, Lorenza Borin, Giulia Quaresmini, Anna Angela Di Tucci, Antonio Volpe, Daniela Cilloni, Giovanni Quarta, Grazia Sanpaolo, Flavia Rivellini, Flavia Salvi, Alfredo Molteni, Maria Teresa Voso, Giuliana Alimena, Susanna Fenu, Franco Mandelli, Emanuele Angelucci. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
BMJ supportive & palliative care.
2016 Mar; 6(1):80-8. doi:
10.1136/bmjspcare-2014-000726. [PMID: 25204541] - Jafar Abolhasani, Roza Naderali, Javad Hassanzadeh. Ag Nanoparticles-enhanced Fluorescence of Terbium-Deferasirox Complexes for the Highly Sensitive Determination of Deferasirox.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
2016; 32(4):381-6. doi:
10.2116/analsci.32.381. [PMID: 27063708] - John B Porter, Mohsen El-Alfy, Vip Viprakasit, Stephane Giraudier, Lee Lee Chan, Yongrong Lai, Ali El-Ali, Jackie Han, Maria D Cappellini. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
European journal of haematology.
2016 Jan; 96(1):19-26. doi:
10.1111/ejh.12540. [PMID: 25691036] - Amir Shokooh Saljooghi, Maryam Babaie, Fatemeh Delavar Mendi, Maliheh Zahmati, Zoheir Shokouh Saljooghi. Chelation of thallium by combining deferasirox and desferrioxamine in rats.
Toxicology and industrial health.
2016 Jan; 32(1):83-8. doi:
10.1177/0748233713498442. [PMID: 24021432]